Drug Profile
ST 793
Alternative Names: TA 803Latest Information Update: 06 Sep 2006
Price :
$50
*
At a glance
- Originator sigma-tau SpA
- Developer Tanabe Seiyaku
- Class Anti-ischaemics; Neuroprotectants; Nootropics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cerebral infarction; CNS disorders; Cognition disorders
Most Recent Events
- 18 Apr 2002 Phase-II clinical trials in Cerebral infarction in Japan (PO)
- 28 Jun 2001 No-Development-Reported for Cerebral infarction in Japan (PO)
- 20 Dec 1997 Phase-II clinical trials for Cerebral infarction in Japan (PO)